Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / ST14



This biomarker is also known as:
  • Serine protease 14,
  • prostamin,
  • OTTHUMP00000230931,
  • Serine protease TADG-15,
  • suppressor of tumorigenicity 14 protein,
  • Tumor-associated differentially-expressed gene 15 protein,
  • HAI,
  • Matriptase,
  • Prostamin,
  • tumor associated differentially expressed gene 15 protein,
  • TADG15,
  • SNC19,
  • Membrane-type serine protease 1,
  • TMPRSS14,
  • suppression of tumorigenicity 14 (colon carcinoma),
  • MTSP1,
  • OTTHUMP00000230932,
  • suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin),
  • EC,
  • MT-SP1,
  • PRSS14,
  • EC 3.4.21,
  • Q9Y5Y6,

View in BioMuta


ST14 protein is an epithelial-derived, integral membrane serine protease and is found to be activated by sphingosine 1-phosphate. The expression of this protease has been associated with breast, colon, prostate, and ovarian tumors, which implicates its role in cancer invasion, and metastasis.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: ST14


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


ST14 localized to vascular-like structures in ovarian cancer but not in normal ovaries.

Performance Comment

ST14 was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of ST14 was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.